Jacobs Levy Equity Management Inc. Takes Position in Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI)

Jacobs Levy Equity Management Inc. bought a new stake in shares of Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor bought 91,909 shares of the company’s stock, valued at approximately $501,000.

A number of other hedge funds and other institutional investors have also recently modified their holdings of MRVI. Performa Ltd US LLC raised its holdings in Maravai LifeSciences by 614.3% during the 4th quarter. Performa Ltd US LLC now owns 5,000 shares of the company’s stock valued at $27,000 after buying an additional 4,300 shares during the period. Farther Finance Advisors LLC raised its holdings in Maravai LifeSciences by 3,541.4% during the 4th quarter. Farther Finance Advisors LLC now owns 10,196 shares of the company’s stock valued at $56,000 after buying an additional 9,916 shares during the period. Cibc World Markets Corp purchased a new stake in Maravai LifeSciences during the 4th quarter valued at $56,000. Atria Investments Inc purchased a new stake in Maravai LifeSciences during the 4th quarter valued at $58,000. Finally, Townsquare Capital LLC purchased a new stake in Maravai LifeSciences during the 4th quarter valued at $103,000. 50.25% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

MRVI has been the topic of several recent research reports. Robert W. Baird decreased their price target on Maravai LifeSciences from $3.00 to $2.00 and set a “neutral” rating on the stock in a report on Tuesday, May 13th. Bank of America reduced their target price on Maravai LifeSciences from $9.00 to $8.00 and set a “buy” rating on the stock in a research note on Monday, March 3rd. UBS Group reduced their target price on Maravai LifeSciences from $8.00 to $2.50 and set a “neutral” rating on the stock in a research note on Friday, March 21st. Morgan Stanley reduced their target price on Maravai LifeSciences from $7.00 to $5.00 and set an “equal weight” rating on the stock in a research note on Tuesday, March 25th. Finally, Craig Hallum reduced their target price on Maravai LifeSciences from $12.00 to $10.00 and set a “buy” rating on the stock in a research note on Tuesday, May 13th. One investment analyst has rated the stock with a sell rating, seven have assigned a hold rating and four have issued a buy rating to the company. According to data from MarketBeat.com, Maravai LifeSciences has a consensus rating of “Hold” and a consensus target price of $6.64.

Maravai LifeSciences Stock Performance

Shares of Maravai LifeSciences stock opened at $2.10 on Friday. The firm has a market cap of $534.11 million, a P/E ratio of -1.28 and a beta of 0.19. The company has a current ratio of 10.74, a quick ratio of 9.94 and a debt-to-equity ratio of 0.89. Maravai LifeSciences Holdings, Inc. has a 12 month low of $1.67 and a 12 month high of $11.50. The stock’s fifty day moving average price is $2.09 and its 200-day moving average price is $4.03.

Maravai LifeSciences (NASDAQ:MRVI) last announced its quarterly earnings results on Monday, May 12th. The company reported ($0.08) EPS for the quarter, missing the consensus estimate of ($0.07) by ($0.01). The firm had revenue of $46.85 million for the quarter, compared to analysts’ expectations of $44.01 million. Maravai LifeSciences had a negative net margin of 81.13% and a negative return on equity of 6.61%. The business’s quarterly revenue was down 26.9% compared to the same quarter last year. On average, equities research analysts expect that Maravai LifeSciences Holdings, Inc. will post -0.24 earnings per share for the current fiscal year.

About Maravai LifeSciences

Maravai LifeSciences Holdings, Inc, a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company’s products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species.